These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27190361)

  • 1. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
    Fell LH; Seiler-Mußler S; Sellier AB; Rotter B; Winter P; Sester M; Fliser D; Heine GH; Zawada AM
    Nephrol Dial Transplant; 2016 Nov; 31(11):1835-1845. PubMed ID: 27190361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct immunologic effects of different intravenous iron preparations on monocytes.
    Fell LH; Zawada AM; Rogacev KS; Seiler S; Fliser D; Heine GH
    Nephrol Dial Transplant; 2014 Apr; 29(4):809-22. PubMed ID: 24523357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
    Hempel JC; Poppelaars F; Gaya da Costa M; Franssen CF; de Vlaam TP; Daha MR; Berger SP; Seelen MA; Gaillard CA
    Am J Nephrol; 2017; 45(1):49-59. PubMed ID: 27889746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
    Pollock RF; Muduma G
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 7. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
    Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
    Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
    Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Importance of the different i.v. iron generations for everyday medical practice].
    Biggar P; Hahn KM
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis.
    Gouwy M; Ruytinx P; Radice E; Claudi F; Van Raemdonck K; Bonecchi R; Locati M; Struyf S
    PLoS One; 2016; 11(11):e0166006. PubMed ID: 27828999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
    Schaefer B; Würtinger P; Finkenstedt A; Braithwaite V; Viveiros A; Effenberger M; Sulzbacher I; Moschen A; Griesmacher A; Tilg H; Vogel W; Zoller H
    PLoS One; 2016; 11(12):e0167146. PubMed ID: 27907058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
    Praschberger M; Haider K; Cornelius C; Schitegg M; Sturm B; Goldenberg H; Scheiber-Mojdehkar B
    Biometals; 2015 Feb; 28(1):35-50. PubMed ID: 25326244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
    Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
    Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
    Wilson PD; Hutchings A; Jeans A; Macdougall IC
    J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
    Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
    Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
    Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.